Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Wegovy: Novo Nordisk’s name-brand version of injectable semaglutide to help adults and children 12 years and older with ...

Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

However, the clock is ticking. Novo Nordisk already has an oral semaglutide to treat type 2 diabetes, sold under the brand name Rybelsus, and they're trialing a high-dose version of that pill that ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Novo Nordisk’s executive president of development Martin Holst ... An oral version of semaglutide, however, under the brand ...